95 related articles for article (PubMed ID: 19318372)
1. Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Ono A; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yasui H; Yamazaki K; Yoshino T; Taku K; Kojima T
Jpn J Clin Oncol; 2009 May; 39(5):332-5. PubMed ID: 19318372
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
3. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Takahari D; Shimada Y; Takeshita S; Nishitani H; Takashima A; Okita N; Hirashima Y; Kato K; Hamaguchi T; Yamada Y; Shirao K
Gastric Cancer; 2010 Aug; 13(3):186-90. PubMed ID: 20820988
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
5. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Lv F; Liu X; Wang B; Guo H; Li J; Shen L; Jin M
Int J Clin Exp Pathol; 2014; 7(6):3293-8. PubMed ID: 25031751
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Goto A; Sukawa Y; Igarashi H; Onodera K; Aoki Y; Suzuki K; Yonezawa K; Yawata A; Kobayashi T; Kaneto H; Shimizu H; Wakasugi H; Matsunaga Y; Itoh M; Okuda H; Arimura Y; Shinomura Y
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1461-6. PubMed ID: 21945893
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
9. [Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].
Sunaga T; Suzuki S; Harada N; Tanaka S; Hayashi T; Suzuki M
Gan To Kagaku Ryoho; 2009 Apr; 36(4):589-93. PubMed ID: 19381029
[TBL] [Abstract][Full Text] [Related]
10. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Shimoyama R; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N; Todaka A; Tomita H; Sakamoto T; Tsushima T
Gastric Cancer; 2009; 12(4):206-11. PubMed ID: 20047125
[TBL] [Abstract][Full Text] [Related]
11. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Lv F; Liu X; Wang B; Guo H; Li J; Shen L; Jin M
Int J Clin Exp Pathol; 2014; 7(7):4274-9. PubMed ID: 25120809
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.
Yoshida T; Yoshikawa T; Tsuburaya A; Kobayashi O; Hasegawa S; Osaragi T; Sairenji M
Anticancer Res; 2006; 26(2B):1595-8. PubMed ID: 16619577
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
14. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Yasui H; Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2009 May; 39(5):315-20. PubMed ID: 19403734
[TBL] [Abstract][Full Text] [Related]
16. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
Satoh S; Kawashima K; Matsumoto S; Hasegawa S; Okabe H; Nomura A; Yoshibayashi H; Watanabe G; Nagayama S; Fukushima M; Sakai Y
Chemotherapy; 2007; 53(3):226-32. PubMed ID: 17356271
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Nakashima K; Hironaka S; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2008 Dec; 38(12):810-5. PubMed ID: 18988666
[TBL] [Abstract][Full Text] [Related]
20. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
